NASDAQ: IPEXInflection Point Acquisition Corp V Stock
$10.38+0.50 (+5.06%)
Updated Sep 17, 2026
IPEX Price
$10.38
Fair Value Price
N/A
Market Cap
$46.00M
52 Week Low
$6.00
52 Week High
$12.11
P/E
-345.83x
P/B
-6.56x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$246.58k
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.02
Operating Cash Flow
-$735k
Beta
-0.01
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IPEX Overview
Description: Inflection Point Acquisition Corp V is a Special Purpose Acquisition Company (SPAC) established with the specific aim of completing a business merger or acquisition. This entity was formerly known as Maywood Acquisition Corp. It successfully held its initial public offering (IPO) on February 13, 2025, distributing 7.5 million units, each valued at US$10.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IPEX's potential to beat the market
- IPEX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Shell Company
Industry Rating
F
IPEX
RankedUnranked of 26
RankedUnranked of 26
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.89 | C | |
| $11.00 | C | |
| $15.03 | C |
Be the first to know about important IPEX news, forecast changes, insider trades & much more!
IPEX News
Overview
Due Diligence Score
–
Industry Average (8)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IPEX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IPEX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IPEX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
IPEX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more IPEX due diligence checks available for Premium users.
Valuation
IPEX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-345.83x
Industry
15.84x
Market
45.05x
IPEX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-6.56x
Industry
115.14x
IPEX's financial health
Profit margin
Revenue
$0.0
Net Income
$357.5k
Profit Margin
0%
IPEX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$91.1M
Liabilities
$7.2M
Debt to equity
-1.02
IPEX's short-term liabilities ($2.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IPEX's long-term liabilities ($4.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IPEX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IPEX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$49.6k
Investing
$0.0
Financing
$100.0k
IPEX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IPEX vs Shell Company Stocks
Inflection Point Acquisition V Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.